Insulet stock (US45784P1012): Benchmark starts coverage with Buy rating

Benchmark initiated coverage of Insulet with a Buy rating and $250 price target on May 12, 2026, highlighting growth in tubeless insulin delivery systems amid US diabetes market expansion.

Insulet Corporation, maker of the Omnipod tubeless insulin pump, received fresh analyst attention as Benchmark initiated coverage with a Buy rating and $250 price target on May 12, 2026. The call underscores the company's position in the growing US diabetes management sector, where Insulet derives a significant portion of its revenue. The stock closed at $154.17 on Nasdaq on May 11, 2026, according to MarketBeat as of 05/12/2026.

Separately, Insulet announced in May 2026 the establishment of a Middle East regional headquarters in Riyadh, Saudi Arabia, marking expansion beyond its core US market that accounts for 72.2% of net sales as of end-2025, per Marketscreener as of 05/12/2026. The firm employs 5,400 people and operates production sites in the US and China.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Insulet Corporation
• Sector/industry: Medical Equipment, Supplies & Distribution
• Headquarters/country: Acton, Massachusetts, USA
• Core markets: US (72.2% of sales)
• Key revenue drivers: Omnipod insulin delivery systems
• Home exchange/listing venue: Nasdaq (PODD)
• Trading currency: USD

Insulet: core business model

Insulet specializes in tubeless insulin delivery systems, with its flagship Omnipod family of wearable pumps and consumable Pods at the center. The company designs, manufactures, and sells these devices for people with diabetes, focusing on convenience over traditional tubed pumps. Headquartered in Acton, Massachusetts, Insulet targets insulin-dependent patients in the US and internationally.

The model emphasizes recurring revenue from Pod consumables, which pair with the durable pump hardware. This structure supports steady cash flows amid rising diabetes prevalence in the US, where the firm holds strong market exposure as a Nasdaq-listed player.

Main revenue and product drivers for Insulet

Omnipod products drive the bulk of revenue, with US sales comprising 72.2% of net sales at end-2025, according to Marketscreener as of 05/12/2026. The company also offers non-insulin subcutaneous drug delivery systems across therapeutic areas. Earnings growth is projected at 24.57% for the coming year to $8.01 per share from $6.43, per MarketBeat data.

In a recent quarter, Insulet reported $1.42 EPS, beating estimates of $1.19, with revenue up 33.9% year-over-year, as noted on MarketBeat as of 05/12/2026. Market cap stood at $12.12 billion as of May 2026 per Nasdaq.

Industry trends and competitive position

The diabetes device market benefits from increasing US prevalence, with Insulet's tubeless technology differentiating it from rivals. Benchmark's Buy initiation reflects optimism on innovation pipeline, including wearable medical devices. The stock's P/E of 35.84 trails the market average of 38.44, suggesting relative value.

Why Insulet matters for US investors

As a Massachusetts-based Nasdaq stock, Insulet offers US investors direct exposure to medical tech innovation in diabetes care, a sector tied to domestic healthcare spending. With production in the US and strong revenue from American markets, it aligns with trends in chronic disease management relevant to retail portfolios.

Conclusion

Benchmark's Buy rating and $250 target highlight Insulet's growth potential in insulin delivery, complemented by international expansion like the Riyadh hub. With solid US revenue and recent earnings beats, the company remains a key player in medtech. Investors track ongoing product developments and market dynamics in diabetes care.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.